Valeo Pharma Inc VPHIF

Healthcare

Valeo Pharma Inc. is a Canadian pharmaceutical company. The Company acquires, or in-licenses branded pharmaceuticals and hospital specialty products for sale in Canada. The Company is engaged in the commercialization of prescription products in Canada with a focus on respiratory/allergy, ophthalmology and hospital specialty products. Its respiratory/allergy products include Enerzair Breezhaler, Atectura Breezhaler and Allerject. The ophthalmology products include Xiidra and Simbrinza. Its specialty products include Redesca, Onstryv, M-Eslon, Yondelis and Ametop Gel 4%. The Company's wholly owned subsidiary is VPI Pharmaceuticals Inc.

GREY:VPHIF - Post by User

Valeo Pharma Inc > 1.20

<< Previous

Bullboard Posts

Next >>

Comment by kooter33on Jun 07, 2021 4:28pm

169 Views

Post# 33342283

RE:1.20

JACKTHEBEAR2 wrote: When we crack 1.20 things should work towards 1.40 and a new range without news will take place. Bottom line this is worth alot more then current levels.The science will bare fruit soon.

Valeo needs institutional support, they have 2 analysts reports which show that the next 12 months VPH should be at $3.30 to $3.50. Right now all we are seeing is a "rinse and repeat" accumulation 1.10 to 1.15 again and again. This company is in a near term explosive growth phase and it will be demonstrated upon the release of Q2 and Q3 reports. Multiple quarters coming of increased revenues and profitable next year.
I am willing to wait and accumulate the rinse and repeat procedure until it shows signs of breaking out and then I will stop accumulating and watch the ascension to the analysts targets within the next 12 months or sooner. JMHO.

<< Previous

Bullboard Posts

Next >>

Paramount Resources signs $3.32 billion asset sale